LEFTY2

- Profound effects on muscle gain, fat loss, and insulin sensitization, along with a dual anabolic/anti-resorptive action on bone, pave the way for Phase 2 clinical development THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- AliveGen USA Inc. (AliveGen), a clinical-stage biopharmaceutical company dedicated to developing first-in-class and best-in-class therapeutics for treating muscle wasting, metabolic disorders, and neuromuscular diseases, is delighted to announce the successful completion of its Phase 1b multiple-ascending dose (MAD) clinical trial for ALG-801. ALG-801 is a novel, next-generation ligand trap, which selectively sequesters a subset of TGF-beta family, including growth differentiation factors and activins. The Phase 1b MAD clinical study was conducted in healthy volunteers. This achievement marks a significant milestone in AliveGen’s mission to discover and deliver innovative therapies that address unmet medical needs. Key Highlights: Study Design: The Phase 1b MAD study is a randomized double-blind placebo-controlled trial in postmenopausal women. Safety Profile: ALG-801 was found to be safe and well-tolerated across all dosing cohorts. Efficacy Signal: ALG-801 exhibited linear pharmacokinetic (PK) exposures, along with dose-dependent and statistically significant pharmacodynamic (PD) responses. These included muscle gain, fat loss, and increased insulin sensitivity, as well as a dual anabolic/anti-resorptive effect on bone. These findings highlight ALG-801’s therapeutic potential in treating a wide range of medical conditions, such as muscle wasting, obesity, cardiometabolic disorders, neuromuscular diseases, chronic kidney disease, liver steatosis and fibrosis, and osteosarcopenia in old age. Differentiated Mechanism: By selectively inhibiting multiple ligands of the Smad2/3 signaling pathway, ALG-801 demonstrates an outstanding efficacy and metabolic effect. Next Step: Following the successful Phase 1b MAD study, AliveGen plans to advance ALG-801 to Phase 2 clinical development. “We are grateful to the healthy volunteers and healthcare professionals who actively participated in our Phase 1b clinical trial,” said HQ Han, MD, PhD, CEO of AliveGen. “We are thrilled with the excellent dose-response data on muscle gain, fat lose, and insulin sensitization from our Phase 1b MAD study. ALG-801, an innovative and powerful therapeutic approach, holds significant promise for addressing unmet needs across a diverse range of diseases. We look forward to advancing ALG-801 into Phase 2 clinical development.” About AliveGen AliveGen USA Inc. is a privately held biopharmaceutical company located in Thousand Oaks, California. The company is focused on the discovery and development of next-generation biotherapeutics to treat the debilitating muscle wasting and loss of functional capacity as occurs in various metabolic disorders, neuromuscular diseases, and age-related frailty.

Presentation will highlight publicly for the first time preclinical data on Bonum’s lead cLAG3-IL2 program, demonstrating the power of its conditionally active platform. SEATTLE--(BUSINESS WIRE)-- Bonum Therapeutics, a biopharmaceutical company that is using innovative technology for conditional regulation to create highly active and less toxic medicines, today announced the first public presentation of preclinical data on its lead program, a conditionally active LAG3-IL2 therapeutic. Scientists from Bonum will present these data in a poster at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024, taking place April 5-10 in San Diego, CA. Presentation details are as follows: Abstract Title: “A novel method for generating regulated cytokine therapeutics: Safety and activity of a conditionally active cLAG3-IL2 capable of delivering IL2 to LAG3+ cells while remaining inert on LAG3- cells.” Presenter: Justin Killebrew, PhD, Senior Director, Immuno-Oncology Discovery at Bonum Therapeutics Abstract Number: 4062 Date/Time: Tuesday, April 9, 2024, 9:00 AM - 12:30 PM PT Session Title: Immune Modulation with Cytokines The poster presentation will highlight a conditionally active therapeutic called cLAG3-IL2 that targets IL-2 to LAG3+ cells while remaining systemically inert, even at high treatment doses. The in vivo safety and efficacy data described in the poster demonstrate that this program is suitable for progressing into the clinic. John Mulligan, PhD, Bonum Therapeutics’ CEO, commented, “We are excited with the progress of our lead program, cLAG3-IL2, and are eager to make the first public presentation about the program at AACR.” The poster will be available on the Bonum website on the day of the presentation. Bonum is developing new therapies based on its proprietary platform of conditionally active therapeutics. The company is a spinout of Good Therapeutics, which developed the technology that Bonum is advancing. The merits of the platform were validated by the Roche acquisition of Good Therapeutics and its PD-1-regulated IL-2 program in September 2022. Bonum’s core platform enables the engineering and development of a broad array of important medicines. Initially, Bonum is applying the technology to regulated cytokines, including IL-12, IFN-alpha, and TGF-beta for immuno-oncology applications. In parallel, it is seeking partners for applications of its technology in other disease areas where the partner brings expertise in a specific biology and can help guide choices to create new therapies and reach patients as quickly as possible. About Bonum Therapeutics Bonum Therapeutics is a privately held biotechnology company focused on the generation of a new class of therapeutics based on a proven technology platform that utilizes principles of allosteric regulation to create highly active and less toxic medicines. The company was founded in 2022 as a spinout of Good Therapeutics, following the sale of Good to Roche in September 2022 for $250 million, plus significant milestones. Using a novel approach, Bonum’s molecules combine a sensor component directed against a specific biological marker and a therapeutic component. When the sensor binds its target, the molecule reversibly changes shape and becomes active, delivering potent activity only where it is needed. The technology is applicable to a wide range of therapeutic areas, including oncology, autoimmunity, metabolic disorders, and pain management. Bonum’s initial efforts are focusing on regulated immunocytokines, including conditionally active IFN-alpha, IL-12, and TGF-beta, while it pursues additional applications in partnership with others. The company is backed by a group of leading venture investors including Rivervest Venture Partners, Roche Venture Fund, Digitalis Ventures, American Century Investments, Codon Capital, and Vivo Capital. For more information, please visit our website at and connect with us on LinkedIn and X (Twitter). View source version on businesswire.com: Contacts Bonum Contact: Neela Patel, PhD Bonum Therapeutics (425) 375-5369 patel@bonumtx.com Source: Bonum Therapeutics View this news release online at:

Potent Activation of Naturally Occurring “Healing Cells” That Amplify Therapeutic Effects of Stem Cells Discovered ELK CITY, Idaho--(BUSINESS WIRE)-- Therapeutic Solutions International, Inc. (TSOI), announced today results of ongoing experiments demonstrating that the healing effects of JadiCells appear to be mediated by a biological mechanism involving interplay between two types of immunological cells found in the body. Using the inflammation-induced lung injury model, the Company found that JadiCell administration caused an increase in monocytes expressing the cytokine interleukin-35 as well as T cells expressing an anti-inflammatory molecule called TGF-beta. Depletion of either of these cells significantly reduced therapeutic effects of JadiCells. Additionally, transfer of monocytes and T cells from JadiCell treated mice was able to protect naïve mice from lung injury. The therapeutic effect of JadiCells was amplified by administration of Leukine (GM-CSF), which is known to increase circulating monocytes. “The data announced today, for which we have filed an additional patent, represents a major step in elucidating the mechanisms of how this incredible cell functions biologically,” said Dr. Thomas Ichim, Board Member of the Company, and Co-inventor of the patent “My mentor has always told me to follow the science. This has been and will continue to be the mantra of our Company as we progress in both clinical advancement of this cell under Right to Try as well as pursuing our filed INDs and new ones which are in the works.” The Company has licensed the issued U.S. Patent No. 9,803,176 B2 covering the use of JadiCells exclusively in the area of brain and lung diseases. A published study demonstrated safety and efficacy of these cells in COVID-19 lung injury and the FDA has cleared a Phase III trial of these cells for COVID-19. Currently the Company is seeking to initiate the Phase III trial in all-cause induced acute respiratory distress syndrome (ARDS), in order to significantly expand the population of eligible patients. “Understanding yet another mechanism of how our therapeutic product functions, provides additional intellectual property, new ways of increasing its efficacy, as well as potentially accelerating development through regulatory agencies,” said Timothy Dixon, President, and CEO of the Company and co-inventor. “ARDS affects 198,000 Americans per year, with a 60% chance of survival under standard of care. We are dedicated to curing this terrible disease1 and making our cells the new standard of care.” About Therapeutic Solutions International, Inc. Therapeutic Solutions International is focused on immune modulation for the treatment of several specific diseases. The Company's corporate website is . 1